Demant A/S (OTCMKTS:WILYY) Hits New 1-Year High – Time to Buy?

Demant A/S Unsponsored ADR (OTCMKTS:WILYY) reached a new 52-week high during trading on Tuesday . The company traded as high as $22.34 and last traded at $22.34, with a volume of 1400 shares trading hands. The stock had previously closed at $20.66.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. UBS Group cut shares of Demant A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. Morgan Stanley raised shares of Demant A/S from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, June 23rd. Zacks Research upgraded shares of Demant A/S to a “hold” rating in a report on Friday, June 26th. Finally, Sanford C. Bernstein cut shares of Demant A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Demant A/S Stock Up 2.1%

The firm’s 50-day moving average price is $20.26 and its 200-day moving average price is $17.32. The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 1.65.

Demant A/S Company Profile

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.